Insurers cut back GLP-1 coverage as demand soars: Found study
$ 32.99 · 4.9 (565) · In stock
As demand surges for GLP-1 therapies, insurers are pulling back on coverage, according to new data from obesity care provider Found. | Sarah Jones Simmer, CEO of Found, said that the trends are likely the result of irresponsible prescribing for recreational reasons causing the pendulum to swing "all the way in the other direction," and it's leading to patients who have genuine medical need struggling to access these therapies.
New Classes Of Obesity Drugs Face Strong Headwinds From Insurers
Why Won't Your Company Pay for Weight-Loss Drugs Like Wegovy
Tsunami of exclusion': Patients face aftermath of GLP-1 cuts
Ozempic, Wegovy and other drugs: Who are they for?
The Rise of GLP-1 Receptor Agonists and Coverage Challenges
The Rise of GLP-1 Receptor Agonists and Coverage Challenges
Ozempic: How the Diabetes Drug Works and Why It's Such a Big Deal for Weight Loss - WSJ
Maker of Wegovy, Ozempic showers money on U.S. obesity doctors
Ozempic is a serious drug with serious risks. Here's what to know.
The Doctor Prescribed an Obesity Drug. Her Insurer Called It 'Vanity.' - The New York Times
Weight-loss drug Wegovy can be marketed for heart benefits after FDA label update
Ozempic coverage is reduced under Ontario Drug Benefit Plan
Can Wegovy Fight Alcoholism? For Big Pharma, This Isn't a Priority
indiablog2b.png